{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443973799
| IUPAC_name = 2,5-dihydroxybenzenesulfonic acid; N-ethylethanamine
| image = Ethamsylate.png
| image2 = Etamsylate ball-and-stick animation.gif

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|etamsylate}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|CAS}}
| CAS_number = 2624-44-4
| ATC_prefix = B02
| ATC_suffix = BX01
| PubChem = 17506
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 24YL531VOH
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01282
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 16553

<!--Chemical data-->
| C=10 | H=17 | N=1 | O=5 | S=1 
| molecular_weight = 263.31068 g/mol
| smiles = CCNCC.c1cc(c(cc1O)S(=O)(=O)O)O
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C6H6O5S.C4H11N/c7-4-1-2-5(8)6(3-4)12(9,10)11;1-3-5-4-2/h1-3,7-8H,(H,9,10,11);5H,3-4H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = HBGOLJKPSFNJSD-UHFFFAOYSA-N
}}

'''Etamsylate''' ('''Dicynene/Dicynone''') is a [[haemostatic]] [[drug]].<ref name="pmid15613570">{{cite journal |last1=Schulte J|first1=J|last2=Osborne|first2=J|last3=Benson|first3=JW|last4=Cooke|first4=R|last5=Drayton|first5=M|last6=Murphy|first6=J|last7=Rennie|first7=J|last8=Speidel|first8=B|title=Developmental outcome of the use of etamsylate for prevention of periventricular haemorrhage in a randomised controlled trial |journal=Arch. Dis. Child. Fetal Neonatal Ed. |volume=90 |issue=1 |pages=F31–5 |date=January 2005 |pmid=15613570 |pmc=1721806 |doi=10.1136/adc.2003.035790 }}</ref><ref name="pmid11320045">{{cite journal |vauthors=Elbourne D, Ayers S, Dellagrammaticas H, Johnson A, Leloup M, Lenoir-Piat S |title=Randomised controlled trial of prophylactic etamsylate: follow up at 2 years of age |journal=Arch. Dis. Child. Fetal Neonatal Ed. |volume=84 |issue=3 |pages=F183–7 |date=May 2001 |pmid=11320045 |pmc=1721248 |doi= 10.1136/fn.84.3.F183|url=http://fn.bmj.com/cgi/pmidlookup?view=long&pmid=11320045}}</ref>

It is believed to work by increasing [[capillary]] [[endothelial]] resistance and promoting [[platelet]] adhesion.

It also inhibits [[biosynthesis]] and action of those [[prostaglandin]]s which cause platelet disaggregation, [[vasodilation]] and increased capillary permeability.<ref name="pmid7319004">{{cite journal|last=Kovács|first=L|author2=Falkay, G|title=Etamsylate as inhibitor of prostaglandin biosynthesis in pregnant human myometrium in vitro.|journal=Experientia|date=Nov 15, 1981|volume=37|issue=11|pages=1182–3|pmid=7319004|doi=10.1007/BF01989908}}</ref>

==Indications==
Prophylaxis and control of haemorrhages from small blood vessels, neonatal intraventricular haemorrhage,<ref>Martindale, The Complete Drug Reference, 36th edition, page: 1065 Drug-Etamsylate</ref> capillary bleeding of different etiology, including: menorrhagia and metrorrhagia without organic pathology, after trans-urethral resection of the prostate, hematemesis, melena, hematuria, epistaxis; secondary bleeding due to thrombocytopenia or thrombocytopathia, hypocoagulation, prevention of periventricular hemorrhages in prematurely born children.<ref>[http://www.sopharma.com/pharmacynon.phtml Bulgarian Pharmaceutical Group Ltd.]</ref>

==Mechanism of action==
Ethamsylate is a haemostatic agent; also promotes [[angioprotective]] and proaggregant action. It stimulates [[thrombopoiesis]] and their release from bone marrow. Haemostatic action is due to activation of thromboplastin formation on damaged sites of small blood vessels and decrease of PgI2 ([[Prostacyclin]] I2) synthesis; it also facilitates platelet aggregation and [[adhesion]], that at last induce decrease and stop of hemorrhage.<ref name="regmed">{{cite web
 |date        = 2008-03-27
 |url         = http://www.regmed.ru/search.asp
 |title       = Поиск по базе данных ЛС, опции поиска: МНН — ''Этамзилат'', флаги ''"Искать в реестре зарегистрированных ЛС"'', ''"Искать ТКФС"'', ''"Показывать лекформы"''
 |work        = Обращение лекарственных средств
 |publisher   = ФГУ «Научный центр экспертизы средств медицинского применения» Росздравнадзора РФ
 |accessdate  = 7 April 2008
 |deadurl     = yes
 |archiveurl  = https://www.webcitation.org/618KN21rk?url=http://www.regmed.ru/search.asp
 |archivedate = 22 August 2011
 |df          = 
}}</ref>

The precise mechanism of action of etamsylate is unknown. It has been shown to reduce bleeding time and blood loss from wounds. This appears to relate to increased platelet aggregation mediated by a thromboxane A2 or prostaglandin F2a dependent mechanism. It has also been associated with decreased concentrations of 6-oxoprostaglandin F1a, a stable metabolite of prostacyclin. Prostacyclin is a potent vasodilator, and may be implicated in reperfusion; it is also a disaggregator of platelets. Whereas prostaglandins themselves may have a role in regulating cerebral blood flow, etamsylate appears to have no effect on cerebral blood flow. Etamsylate was also thought to stabilise capillaries, reinforcing capillary membranes by polymerising hyaluronic acid. 
<ref name="pmid15613569">{{cite journal|last=Hunt|first=RW|title=Etamsylate for prevention of periventricular haemorrhage.|journal=Archives of Disease in Childhood: Fetal and Neonatal Edition|date=January 2005|volume=90|issue=1|pages=F3–5|url=http://fn.bmj.com/content/90/1/F3.full.pdf|pmid=15613569|doi=10.1136/adc.2003.045625|pmc=1721808}}</ref>
Etamsylate limits capillary bleeding through its action on hyaluronic acid and initial studies showed a reduction in intraventricular haemorrhage.<ref>Martindale, The Complete Drug Reference, 36th edition - page 1050</ref> 
Etamsylate may also have an effect on the microcirculation, encouraging platelet aggregation and vasoconstriction and therefore haemostasis. It also inhibits the effects of the prostaglandin mediated vasodilatation and increased capillary permeability, thereby reducing oedema secondary to capillary leakage. It is also possible that etamsylate would reduce reperfusion haemorrhage in ischaemic areas of the brain, preventing secondary damage.
<ref name="pmid15613570"/>
By inhibiting the effects of prostaglandins, etamsylate may exert an effect by closing the patent ductus
and thereby increasing cerebral blood flow.<ref name="pmid6795324">{{cite journal|last=Perlman|first=Jeffrey M.|author2=Hill, Alan |author3=Volpe, Joseph J. |title=The effect of patent ductus arteriosus on flow velocity in the anterior cerebral arteries: Ductal steal in the premature newborn infant|journal=The Journal of Pediatrics|date=1 November 1981|volume=99|issue=5|pages=767–771|doi=10.1016/S0022-3476(81)80408-8|pmid=6795324}}</ref>

==References==
{{reflist}}

{{Antihemorrhagics}}
{{Vasoprotectives}}

[[Category:Benzenesulfonic acids]]
[[Category:Hydroquinones]]